Breast cancer care across CION centres in Hyderabad · ArogyaSri, CGHS & cashless insurance accepted · Call 1800 202 8726
Breast Cancer Screening & Early Detection · Hyderabad

Breast Cancer Screening: Guidelines, High-Risk & Early Detection

Breast cancer found early is one of the most treatable of all cancers — at CION, 1-year survival for breast cancer is 96.9% versus a national average of 85.4%.* Screening is simply checking a healthy breast for cancer before any lump or symptom appears, so it can be caught at its smallest, most curable stage. But the right test and the right age differ from woman to woman: an average-risk woman, a woman with a family history, and a woman with dense breasts each need a different plan. This guide explains when to start, which test you need, and what happens if screening finds something — and at CION, a woman-headed, tumor-board-led team sets up exactly the screening you need, with no rushed decisions and no unnecessary tests.

  • Early detection saves lives — Breast cancer caught at stage 0-1 has close to 100% 5-year survival; screening finds tumours years before they can be felt.
  • The right test for you — Mammogram, ultrasound or MRI — chosen for your age, breast density and risk, not a one-size-fits-all package.
  • A clear screening plan — We assess your risk in a free 45-minute consult and set the exact schedule you need — no more, no less.
  • Woman-led, tumor-board-reviewed — Breast care led by senior specialists; any abnormal finding is reviewed by a panel, not one doctor.
4.8 · 800+ Google reviews · 15,000+ patients treated

Book a consultation

Leave your details and our team will call you back.

Free call back. Your details stay private.

17+
Cancer Specialists
on Panel
96.9%
Breast Cancer
Survival Rate*
15,000+
Patients
Treated
4.8★
Google Rating
(800+ reviews)
Start here

Why breast cancer screening matters — early detection saves lives

The single biggest factor in surviving breast cancer is how early it is found. A screening test can detect a tumour while it is still tiny and confined to the breast — often years before it grows large enough to feel as a lump. Caught at this stage, treatment is usually simpler, gentler and far more successful: breast cancer found at stage 0 or stage 1 has close to 100% five-year survival, while cancer found late, after it has spread, is much harder to treat.

This matters especially in India. Breast cancer is now the most common cancer in Indian women, and it tends to appear about a decade younger than in the West. Yet most cases here are still detected late, when a woman finally notices a lump herself. Regular screening flips that pattern — it is designed to find cancer before symptoms, which is exactly why outcomes are so much better. At CION, breast cancer 1-year survival is 96.9% compared with a national average of 85.4%,* a gap built largely on earlier detection and team-led care.

Found small, treated gently

Screening detects cancers a few millimetres across — often before a lump can be felt — when breast-conserving surgery and milder treatment are far more likely to succeed.

Stage decides survival

Stage 0-1 breast cancer has near 100% 5-year survival; survival falls sharply once cancer spreads to lymph nodes or beyond, so finding it early genuinely changes the outcome.

India's most common cancer in women

Breast cancer is the leading cancer among Indian women and often strikes younger than in the West — yet most cases are still caught late, which screening is designed to prevent.

96.9% vs 85.4% at CION

CION's 1-year breast cancer survival of 96.9% against an 85.4% national average* reflects what earlier detection plus tumor-board-led care can achieve.

Did you know?

Breast cancer is now the most common cancer in Indian women, and on average it appears about a decade younger than in Western countries. Yet a majority of Indian cases are still detected at an advanced stage, because they are found only when a woman notices a lump herself rather than through screening. Screening is designed to find cancer before any symptom appears — which is exactly why it improves survival so dramatically. Source: ICMR National Cancer Registry Programme (NCRP).

When to start

Breast cancer screening guidelines by age and risk

There is no single age that fits everyone. The right schedule depends on whether you are at average risk or high risk, and the major guidelines broadly agree on the framework below.

The Indian Breast Imaging Society, ICMR, the American College of Radiology and the American Cancer Society broadly agree on one idea: average-risk women begin in their 40s, while high-risk women start earlier and add MRI. One firm rule applies to everyone — screening mammography is not started before age 25, whatever the risk, because young breast tissue is too dense to read reliably. The guidance below is a starting point, not a prescription; your own plan should be set by a specialist who knows your family history, breast density and personal risk. At CION, that assessment is part of your free first consultation.

Average risk, 25-39: know your breasts

Monthly breast self-awareness from about age 25, plus a clinical breast examination by a doctor every 1-3 years. Routine mammography is not usually advised at this age because dense young breast tissue makes it hard to read.

Average risk, 40-49: annual mammogram begins

Most Indian and American guidelines advise starting annual (or at least every-2-year) mammography from age 40, together with a yearly clinical breast examination. This is the age at which the benefit of mammography clearly outweighs the small downsides for average-risk women.

Average risk, 50-69: the core screening years

There is universal agreement that women aged 50-69 benefit most from regular mammography — annual or every two years depending on breast density and the guideline followed. Continue clinical breast examination yearly alongside it.

Average risk, 70+: continue while healthy

Indian guidance commonly advises mammography up to about age 70; beyond that, screening is continued as long as you are in good general health and would be fit for treatment if cancer were found. This is an individual decision with your doctor.

High risk: start earlier, add MRI

Women with a strong family history, a known BRCA1/BRCA2 mutation, prior chest radiation, or a calculated lifetime risk of about 20-25% or more are screened from their 30s — annual mammography plus annual breast MRI, often from age 30 (MRI from 25-30 in the highest-risk genetic syndromes).

The screening toolkit

Tests used in breast screening: mammogram, ultrasound, MRI — and when

Screening is not one test but a toolkit, and the right tool depends on your age, breast density and risk.

A mammogram is the backbone of screening for most women. Ultrasound and MRI are added when a mammogram alone isn't enough — typically for younger women, dense breasts, or high-risk women. Understanding what each test does, and when it is used, helps you have a more confident conversation with your specialist rather than simply accepting whatever package a lab offers. A common, costly mistake is choosing a test by price alone: the cheapest scan is not the right one if it can't see your breast tissue clearly. At CION, the test is matched to you — and where a scan is needed, diagnostics are available at up to 50% discount with same-day, expert-reviewed reports.

Mammogram — the screening backbone

A low-dose breast X-ray taken in two views, and the standard screening test for women 40 and over. It can show tiny calcium specks and small masses long before they can be felt. Digital and 3D (tomosynthesis) mammograms read dense breasts better and lower the chance of being called back. In Hyderabad a screening mammogram typically costs around ₹1,500-3,500 (3D mammography more).

Breast ultrasound — for dense and younger breasts

Uses sound waves, no radiation, and is excellent at telling a harmless fluid cyst from a solid lump. It is the preferred first imaging test for women under about 35-40 whose breast tissue is too dense for a clear mammogram, and is frequently added to mammography in dense breasts to catch cancers a mammogram can miss.

Breast MRI — the most sensitive test

A magnetic scan (no radiation) that is the most sensitive way to detect breast cancer, picking up cancers that mammography and ultrasound can miss. Because it can also flag harmless areas, it is reserved for high-risk women — a known BRCA mutation, a strong family history, or prior chest radiation — usually added to an annual mammogram from the 30s.

Clinical breast examination (CBE)

A trained doctor examines both breasts and the underarm lymph nodes by hand, looking and feeling for lumps, skin or nipple changes. It is a simple, low-cost layer recommended yearly from age 40 (and every 1-3 years from the 20s-30s) — useful alongside imaging, especially where access to mammography is limited.

Why the right test beats the cheapest test

A mammogram can miss cancers in dense breasts; an ultrasound may not show the tiny calcifications a mammogram catches. Picking a scan on price alone can give false reassurance. The right combination — decided by a specialist for your age and density — is what actually protects you, and at CION diagnostics come with up to 50% discounts and same-day expert-reviewed reports.

Know your normal

Breast self-exam and clinical breast examination

Imaging is the engine of screening, but two simpler habits sit alongside it — and they matter most for women too young for routine mammography.

Breast self-awareness means knowing how your own breasts normally look and feel, so you notice a change quickly. A clinical breast examination (CBE) is the same idea performed by a trained doctor. Neither replaces a mammogram for women 40 and over, but together they are an important front line — many Indian breast cancers are still first noticed by the woman herself. Be clear about their limits, though: self-examination cannot reliably find the tiny, early cancers a mammogram detects, so it is a complement to screening, never a substitute. The goal is not anxious monthly hunting for lumps, but simply knowing your normal and acting promptly on any change.

Know your normal

Breast self-awareness from about age 20-25 means learning how your breasts usually look and feel through the month, so any new or persistent change stands out — rather than performing a tense, rigid examination.

What to watch for

Report a new lump in the breast or underarm, a change in size or shape, skin dimpling or puckering, nipple turning inward or discharge (especially blood-stained), and persistent redness, rash or pain in one area.

When and how

If you menstruate, check a few days after your period when breasts are least tender; after menopause, pick a fixed day each month. Look in a mirror with arms down then raised, then feel the whole breast and underarm in small circles.

Clinical breast examination (CBE)

A doctor examines both breasts and the lymph nodes by hand. Indian guidance suggests CBE every 1-3 years from the 20s-30s and yearly from 40 — a low-cost layer that is especially valuable where mammography access is limited.

A complement, not a substitute

Self-exam and CBE cannot find the millimetre-sized cancers a mammogram detects, so they do not replace screening for women 40 and over. Their job is to catch changes between scans — and to prompt younger women to see a specialist early.

Talk to our team

Have questions about breast cancer? Speak to a specialist.

Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.

Call 1800 202 8726 Helpline open 24/7

Request a call back

Share your number and a specialist's team will call you.

Free call back. Your details stay private.

Get the right breast screening for your risk — your first consultation is free.

Woman-led, tumor-board-reviewed care across 35+ centres in Telangana & AP, with same-day expert-reviewed reports. Call 1800-202-8726.

Book Free Consultation Call 18002028726
A different plan

Screening for high-risk and dense-breast women

Standard screening is built for average-risk women. Two groups need a more intensive plan: women at high genetic or family risk, and women with dense breasts. They are not the same thing — a woman can be one, the other, or both — but each means a mammogram alone may not be enough.

Who counts as high risk

A known BRCA1/BRCA2 (or other high-risk gene) mutation; a strong family history of breast or ovarian cancer, especially relatives diagnosed young or on both sides; prior chest/mantle radiation, particularly before age 30; or a lifetime risk of roughly 20-25% or more on a validated risk model such as the Tyrer-Cuzick or Gail score.

High-risk schedule: MRI plus mammogram

For high-risk women, guidelines recommend annual screening mammography plus annual breast MRI, typically starting around age 30 (MRI as early as 25-30 in the highest-risk genetic syndromes such as Li-Fraumeni). Where a relative was affected young, screening often begins about 10 years before that relative's age at diagnosis.

What 'dense breasts' means

Breast density describes how much glandular and fibrous tissue you have versus fat; it is reported on your mammogram (BI-RADS categories C and D are 'dense'). It has nothing to do with how breasts feel and cannot be judged by touch — only a mammogram can tell you, and density tends to be higher in younger women.

Why dense breasts need extra imaging

Dense tissue appears white on a mammogram, and so do most tumours — so a cancer can hide in plain sight, lowering a mammogram's sensitivity. Dense breasts also carry a modestly higher cancer risk. For these women, adding ultrasound (and MRI in higher-risk cases) finds cancers that mammography alone would miss.

Supplemental ultrasound for dense breasts

Whole-breast ultrasound is the most common add-on for women with dense breasts who are not high-risk enough to need MRI. It uses no radiation and detects additional cancers, though it does raise the chance of a benign call-back — a trade-off your specialist will weigh with you.

A plan set by your specialist

Being high-risk or having dense breasts does not mean every test, every year — it means the right combination, set deliberately. At CION the tumor board reviews high-risk and dense-breast cases and tailors the schedule, so you are neither under-screened nor over-tested, with diagnostics at up to 50% discount.

High-risk or dense breasts? Get a screening plan built for you.

Share a few details and our team will call to arrange your free, 45-minute, woman-led assessment — with the right combination of mammogram, ultrasound or MRI, and diagnostics at up to 50% off.

By submitting, you consent to be contacted by CION about your enquiry.

After an abnormal result

What happens if screening finds something

This is the part that frightens women most — and it is where most worry turns out to be unnecessary. An abnormal screening result very rarely means cancer.

Out of every 100 women screened, roughly 10 are called back for more pictures, only about 2 go on to a biopsy, and even then most biopsies prove harmless. A call-back is not a diagnosis; it simply means a closer look is needed. If your mammogram shows something unclear, the next steps follow a calm, well-worn path that doctors call triple assessment — combining examination, more detailed imaging, and (only if needed) a biopsy. Knowing this sequence in advance takes much of the fear out of a call-back. At CION every such case is reviewed by the tumor board, so any decision about a biopsy or treatment is made by a team, not a single doctor.

1

A call-back for more imaging

The commonest next step is simply more pictures — extra mammogram views or a targeted ultrasound — to look more closely at the area. Most call-backs end here, with an all-clear or a finding that is clearly harmless, such as a cyst.

2

Triple assessment, if needed

If an area still looks uncertain, doctors combine three things — a clinical examination, detailed imaging (mammogram and/or ultrasound, sometimes MRI), and a needle biopsy — to reach a confident answer. This combined approach is the gold standard and is far more accurate than any one test.

3

A biopsy gives the real answer

Only a biopsy — a thin needle taking a small tissue sample, usually under local anaesthetic — can confirm whether a finding is cancer. Most biopsies turn out benign. If it is cancer, the same sample tells doctors the type and characteristics needed to plan the right treatment.

4

Most results are reassuring

Per 100 women screened, about 90 have no concern, around 10 are recalled, roughly 2 need short-interval follow-up, and about 2 need a biopsy — and most biopsies are not cancer. A call-back is a precaution, not a verdict.

5

A team plans your next step

If cancer is confirmed, you are not handed a single opinion. At CION every case goes to the tumor board — medical, surgical and radiation oncologists together — who agree a plan in a 45-minute consultation, with transparent costs and no unnecessary tests. Decisions for healing, not billing.

Free first consultation

CION breast screening services across Hyderabad + free consultation

Knowing the guidelines is one thing; getting the right screening, conveniently and affordably, is another. CION makes that simple. With 35+ centres across Telangana and AP and PET-CT and diagnostic locations across Hyderabad — Jubilee Hills, Banjara Hills, Punjagutta, Himayatnagar and Narayanaguda — quality breast screening is close to home, with same-day, expert-reviewed reports.

What sets CION apart is not just access but judgement. As a woman-headed, tumor-board-led organisation, we begin with a free 45-minute consultation to assess your real risk and decide which test you actually need — rather than selling a one-size-fits-all package. The pathway below is how a typical screening visit works.

1

Free 45-minute risk consultation

A specialist reviews your age, family history and breast density, examines you if needed, and explains in plain language exactly which screening test you need — and which you don't. Free for all cancer patients, no pressure, no unnecessary tests.

2

The right test, at up to 50% off

Mammogram, ultrasound or MRI as appropriate, across centres in Jubilee Hills, Banjara Hills, Punjagutta, Himayatnagar and Narayanaguda — with up to 50% discounts on diagnostics and same-day, expert-reviewed reports.

3

Tumor-board review if anything is found

Any abnormal result is reviewed by the full tumor board — medical, surgical and radiation oncologists together — so a call-back or biopsy decision is made by a team, not one doctor, with transparent costs throughout.

4

A personalised ongoing plan

You leave with a clear schedule for your future screening — the right test at the right interval for your risk — plus access to nutrition and psycho-oncology support, all backed by 150+ years of combined experience and a 4.8/5 Google rating.

*1-year survival. Source: ICMR / National Cancer Registry Programme (NCRP). CION figures are network outcomes; national figures are population averages and do not predict an individual's result.

Meet the Specialists

17+ senior cancer specialists. One panel for your case.

Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.

Dr. Naresh Gundu
Medical Oncologist

Dr. Naresh Gundu

MBBS, DNB (Internal Medicine), DM (Medical Oncology)

View Profile
Dr. C. Raghavendra Reddy
Medical Oncologist

Dr. C. Raghavendra Reddy

MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)

View Profile
Dr. Bharati Devi Gorantla
Medical Oncologist

Dr. Bharati Devi Gorantla

MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)

View Profile
Dr. Owais Mohammed
Medical Oncologist

Dr. Owais Mohammed

MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)

View Profile
Dr. T. Raghavender Reddy
Medical Oncologist

Dr. T. Raghavender Reddy

MBBS, DM (Medical Oncology), MD (Radiation Oncology)

View Profile
Dr. N. Kiranmayee
Medical Oncologist

Dr. N. Kiranmayee

MBBS, DM (Medical Oncology), MD (Internal Medicine)

View Profile
Dr. Muralidhar Muddusetty
Surgical Oncologist

Dr. Muralidhar Muddusetty

MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)

View Profile
Dr. Raghavendra Naik
Surgical Oncologist

Dr. Raghavendra Naik

MBBS, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile
Dr. Mohammed  Imaduddin
Surgical Oncologist

Dr. Mohammed Imaduddin

M.B.B.S, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile
Dr. Vinay Mamidala
Surgical Oncologist

Dr. Vinay Mamidala

MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)

View Profile
Dr. Paila Gowri Naidu
Surgical Oncologist

Dr. Paila Gowri Naidu

MBBS, MS (General Surgery), M.Ch (Surgical Oncology), FMAS

View Profile
Dr. Venkata Sushma P
Radiation Oncologist

Dr. Venkata Sushma P

MBBS, MD (Radiation Oncology)

View Profile
Dr. Kirti Ranjan Mohanty
Radiation Oncologist

Dr. Kirti Ranjan Mohanty

MBBS, MD (Radiation Oncology)

View Profile
Dr. Gangadhar Vajrala
Radiation Oncologist

Dr. Gangadhar Vajrala

MBBS, MD (Radiation Oncology), MPH

View Profile
Dr. Basudev Pokhrel
Hematologist

Dr. Basudev Pokhrel

MBBS, M.D (Immunohematology & Blood Transfusion)

View Profile
Dr. Vajja Sandeep Kumar
Surgical Oncologist

Dr. Vajja Sandeep Kumar

MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology

View Profile
Dr. Sridhar Kamani
Surgical Oncologist

Dr. Sridhar Kamani

MBBS, MS (General Surgery), DrNB (Surgical Oncology)

View Profile

Want a specific doctor for your case? Mention them when booking.

Book Free Consultation

Where to find us

Our centres in and around Hyderabad

Addressed by landmark, because that is how this city navigates. Each centre also names the areas it serves, so you can place it without a map. Consultation and day-care Chemotherapy run at every one of them.

CION Ameerpet

Beside Blue Fox Hotel, Satyam Theatre Road

Begumpet SR Nagar Punjagutta
CION Kukatpally

Opposite Big Bazaar, Mumbai Highway

KPHB JNTU Bharat Nagar
CION L.B. Nagar

Anu Arcade, next to L.B. Nagar Metro station

Vanasthalipuram Nagole Hayathnagar
CION Tolichowki

Inside Premier Hospital, Khader Bagh Road

Mehdipatnam Attapur Rethibowli
CION Masab Tank

Mahavir Hospital, AC Guards, Lakdikapul

Lakdikapul Khairatabad Basheer Bagh
CION Banjara Hills

Road No. 12

Jubilee Hills Madhapur Film Nagar
CION Kompally

Suchitra Circle, NH-44

Suchitra Circle Alwal Dundigal
CION Balanagar

Balanagar Main Road

Balanagar Fatehnagar Moosapet
CION Siddipet

Lohith Sai Hospital, Shivaji Nagar

Gajwel Husnabad Dubbaka
CION Sangareddy

X Roads, Pothreddipalle

Narayankhed Zaheerabad Patancheru

Talk to our team

Have questions about breast cancer? Speak to a specialist.

Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.

Call 1800 202 8726 Helpline open 24/7

Request a call back

Share your number and a specialist's team will call you.

Free call back. Your details stay private.

Common questions

Breast cancer screening — your questions answered

At what age should I start breast cancer screening?

For women at average risk, most Indian and international guidelines advise starting annual mammography at age 40, with a yearly clinical breast examination. Before 40, the focus is on breast self-awareness and a clinical breast examination every 1-3 years, since dense young breast tissue makes mammograms hard to read. Women aged 50-69 benefit most and should not skip screening. If you are at high risk — a strong family history, a known BRCA mutation, or prior chest radiation — you should start earlier, usually in your 30s, and add an annual breast MRI. One rule applies to everyone: screening mammography is not started before age 25. A specialist can confirm the right starting age for your personal risk.

How often should I get a mammogram?

For average-risk women aged 40 and over, guidelines recommend a mammogram either every year or every two years, depending on your breast density and the guideline followed. Annual screening detects cancers slightly earlier; every-two-year screening means fewer call-backs. Women with dense breasts or any extra risk are usually advised to screen annually. High-risk women have an annual mammogram plus an annual breast MRI. The best interval for you depends on your age, breast density, family history and previous results — which is exactly what a screening consultation is for. At CION, we set your interval individually rather than applying a single rule to everyone.

What is the difference between a mammogram, ultrasound and MRI for breast screening?

A mammogram is a low-dose breast X-ray and the standard screening test for women 40 and over; it is excellent at spotting tiny calcium specks and small masses. A breast ultrasound uses sound waves and no radiation — it is best for younger women and dense breasts, and tells a harmless cyst from a solid lump. A breast MRI is the most sensitive test of all, used mainly for high-risk women (such as those with a BRCA mutation) added to their mammogram. They are not interchangeable: the right test depends on your age, breast density and risk. A specialist matches the test to you rather than selecting by price.

How much does breast cancer screening cost in Hyderabad?

Costs vary by test and centre. In Hyderabad a clinical breast examination is roughly ₹300-800 (sometimes free at awareness camps), a 2D digital mammogram around ₹1,500-3,500, a 3D mammogram around ₹3,000-6,000, a breast ultrasound around ₹1,000-3,000, and a breast MRI from about ₹7,000 upwards. Bundled screening packages combining a mammogram with a consultation are commonly available. Choosing by price alone can be a false economy — the cheapest scan is not the right one if it cannot read your breast tissue clearly. At CION, diagnostics are available at up to 50% discount, and your first consultation to decide which test you actually need is free. Call 1800-202-8726 for a current estimate.

I have dense breasts — does that change my screening?

Often, yes. Dense breasts have more glandular and fibrous tissue, which matters for two reasons. First, dense tissue slightly raises your breast cancer risk. Second, dense tissue appears white on a mammogram and so do tumours, so a cancer can hide and be missed. For this reason, women with dense breasts are frequently advised to add a supplemental breast ultrasound to their mammogram, and high-risk dense-breast women may need MRI. Importantly, you cannot tell breast density by touch — only a mammogram report (graded as BI-RADS C or D) can tell you. If your report says your breasts are dense, ask a specialist whether supplemental imaging is right for you.

Can I just do a breast self-exam instead of a mammogram?

No — they do different jobs and one cannot replace the other. Breast self-awareness means knowing how your breasts normally look and feel so you notice a change quickly, and it is valuable, especially for younger women. But self-examination cannot reliably find the tiny, millimetre-sized cancers that a mammogram detects years before they can be felt. By the time a cancer is large enough to feel as a lump, it is at a later stage than one found by screening. So self-exam is an important complement that catches changes between scans, but for women 40 and over it does not replace regular mammography. Use both: know your normal, and keep your screening appointments.

I was called back after my screening mammogram — does that mean I have cancer?

Almost certainly not. A call-back is very common and is not a diagnosis — it simply means the radiologist wants a closer look at one area. Out of every 100 women screened, around 10 are recalled for more pictures, but only about 2 go on to a biopsy, and most biopsies turn out to be harmless. A call-back usually means extra mammogram views or a targeted ultrasound, which most often shows something clearly benign such as a cyst or normal overlapping tissue. Only if an area still looks uncertain is a biopsy suggested. Try not to panic: the system is designed to be cautious, and the great majority of recalls end with reassuring news.

What happens if my screening finds something abnormal?

You move onto a calm, step-by-step pathway, not straight to treatment. First, you are called back for more detailed imaging — extra mammogram views or an ultrasound. If anything still looks uncertain, doctors use triple assessment: a clinical examination, detailed imaging, and a needle biopsy, combined for an accurate answer. Only a biopsy can confirm whether a finding is cancer, and most biopsies are benign. If cancer is confirmed, the biopsy also reveals the type and characteristics needed to plan treatment. At CION, every such case is reviewed by the tumor board — medical, surgical and radiation oncologists together — so any decision is made by a team, in a 45-minute consultation, with transparent costs.

Does CION offer a free consultation to plan my breast screening?

Yes. CION offers a free first consultation for all cancer patients and women planning their screening. It is a full 45-minute session in which a specialist reviews your age, family history and breast density, examines you if needed, and explains exactly which screening test you need — and which you don't — in plain language. If imaging is needed, diagnostics are available at up to 50% discount with same-day, expert-reviewed reports, across centres in Jubilee Hills, Banjara Hills, Punjagutta, Himayatnagar and Narayanaguda. As a woman-headed, tumor-board-led organisation, we make decisions for healing, not billing — no unnecessary tests. You can book on 1800-202-8726 or request a callback through the form on this page.

Explore more

Breast Cancer Topics

Browse our complete guide to breast cancer — types, symptoms, tests and treatments. Tap any topic to read more.

HER2-Targeted Therapy

Cost of a full year of HER2 therapy in India De-escalated HER2 treatment for small tumours What happens if your heart function drops during treatment? Ejection fraction monitoring on HER2 therapy HER2-low breast cancer HER2-positive and hormone-positive together The full HER2 treatment pathway How does pertuzumab work, and who is it for? How does trastuzumab emtansine work, and who is it for? How long will you be on pertuzumab? Is adding pertuzumab worth the extra cost? Missed a dose of pertuzumab? What to do Missed a dose of trastuzumab emtansine? What to do Neratinib as extended adjuvant HER2 therapy Pertuzumab, fertility, menopause and sexual health How much does pertuzumab actually help? The numbers explained Pertuzumab cost in India Diarrhoea and rash on pertuzumab Heart function monitoring on dual HER2 blockade Pertuzumab infusion day Medicines, foods and supplements to avoid on pertuzumab Tests and monitoring while you are on pertuzumab Pertuzumab myths Pertuzumab (Perjeta) for breast cancer Pertuzumab side effects Pertuzumab T-DM1 infusion day Liver enzyme rises and nerve changes on T-DM1 Low platelets and bleeding risk on T-DM1 T-DM1 myths T-DM1 vs continuing trastuzumab after residual disease Trastuzumab emtansine (T-DM1) after residual disease Trastuzumab biosimilars in India Trastuzumab emtansine, fertility, menopause and sexual health How much does trastuzumab emtansine actually help? The numbers explained Trastuzumab emtansine cost in India Medicines, foods and supplements to avoid on trastuzumab emtansine Trastuzumab emtansine side effects Trastuzumab emtansine (Kadcyla) for breast cancer Lapatinib and tucatinib Why exactly twelve months of trastuzumab?

Hormone Therapy Medicines

Anastrozole, fertility, menopause and sexual health How much does anastrozole actually help? The numbers explained Anastrozole cost in India Medicines, foods and supplements to avoid on anastrozole Cholesterol, bone density and long-term effects of anastrozole Tests and monitoring while you are on anastrozole Anastrozole myths Anastrozole side effects Anastrozole vs tamoxifen Anastrozole (Arimidex) for breast cancer Exemestane, fertility, menopause and sexual health How much does exemestane actually help? The numbers explained Exemestane cost in India Medicines, foods and supplements to avoid on exemestane Joint pain and fatigue on exemestane Tests and monitoring while you are on exemestane Exemestane myths Exemestane side effects Why exemestane is taken after food and its steroidal effects Exemestane (Aromasin) for breast cancer Fulvestrant, fertility, menopause and sexual health How much does fulvestrant actually help? The numbers explained Fulvestrant cost in India Injection site pain and reactions on fulvestrant The fulvestrant injection Medicines, foods and supplements to avoid on fulvestrant Tests and monitoring while you are on fulvestrant Fulvestrant myths Fulvestrant side effects Fulvestrant vs aromatase inhibitors in advanced disease Fulvestrant (Faslodex) for breast cancer How much does goserelin actually help? The numbers explained Bone loss and mood changes on ovarian suppression Goserelin cost in India The goserelin implant Medicines, foods and supplements to avoid on goserelin Sudden menopause symptoms from ovarian suppression Tests and monitoring while you are on goserelin Goserelin myths Goserelin side effects Goserelin injections vs surgical ovary removal Goserelin (Zoladex) for breast cancer Hot flushes, joint pain and fatigue on fulvestrant How does anastrozole work, and who is it for? How does exemestane work, and who is it for? How does fulvestrant work, and who is it for? How does goserelin work, and who is it for? How does letrozole work, and who is it for? Postmenopausal hormone-receptor-positive breast cancer How long will you be on anastrozole? How long will you be on exemestane? How long will you be on fulvestrant? How long will you be on goserelin? How long will you be on letrozole? Taking anastrozole Taking exemestane Taking letrozole Letrozole, fertility, menopause and sexual health How much does letrozole actually help? The numbers explained Bone thinning on letrozole Letrozole cost in India Medicines, foods and supplements to avoid on letrozole Joint pain and morning stiffness on letrozole Tests and monitoring while you are on letrozole Letrozole myths Letrozole side effects Letrozole vs anastrozole vs exemestane Letrozole (Femara) for breast cancer Missed a dose of anastrozole? What to do Missed a dose of exemestane? What to do Missed a dose of fulvestrant? What to do Missed a dose of goserelin? What to do Missed a dose of letrozole? What to do Exemestane after letrozole or anastrozole Will your periods and fertility return after stopping goserelin?

Targeted & Newer Medicines

Abemaciclib, fertility, menopause and sexual health How much does abemaciclib actually help? The numbers explained Abemaciclib cost in India Diarrhoea on abemaciclib Two years of abemaciclib after surgery Medicines, foods and supplements to avoid on abemaciclib Tests and monitoring while you are on abemaciclib Abemaciclib myths Abemaciclib side effects Abemaciclib vs other CDK4/6 inhibitors Abemaciclib (Verzenio) for breast cancer CDK4/6 inhibitors in early breast cancer after surgery Adjuvant olaparib after surgery for BRCA carriers Alpelisib, fertility, menopause and sexual health How much does alpelisib actually help? The numbers explained Alpelisib cost in India High blood sugar on alpelisib Medicines, foods and supplements to avoid on alpelisib Tests and monitoring while you are on alpelisib Alpelisib myths Alpelisib (Piqray) for breast cancer Rash and mouth sores on alpelisib Alpelisib side effects Alpelisib vs everolimus after endocrine therapy fails Alpelisib for PIK3CA-mutated breast cancer CDK4/6 inhibitors in breast cancer Everolimus in hormone-resistant breast cancer How does abemaciclib work, and who is it for? How does ribociclib work, and who is it for? How does sacituzumab govitecan work, and who is it for? How long will you be on alpelisib? How long will you be on ribociclib? How long will you be on sacituzumab govitecan? Taking abemaciclib Taking alpelisib Taking ribociclib Liquid biopsy in metastatic breast cancer Missed a dose of abemaciclib? What to do Missed a dose of alpelisib? What to do Missed a dose of ribociclib? What to do Missed a dose of sacituzumab govitecan? What to do Newer drugs Elacestrant and oral SERDs for ESR1-mutant disease PARP inhibitors for BRCA-mutated breast cancer Do you need a PIK3CA test before alpelisib? Ribociclib, fertility, menopause and sexual health How much does ribociclib actually help? The numbers explained Ribociclib cost in India ECG monitoring and QT prolongation on ribociclib Medicines, foods and supplements to avoid on ribociclib Low white cell counts on ribociclib Tests and monitoring while you are on ribociclib Ribociclib myths Ribociclib side effects Ribociclib (Kisqali) for breast cancer Sacituzumab govitecan, fertility, menopause and sexual health How much does sacituzumab govitecan actually help? The numbers explained Sacituzumab govitecan cost and availability in India Diarrhoea on sacituzumab govitecan and how it is managed Medicines, foods and supplements to avoid on sacituzumab govitecan Tests and monitoring while you are on sacituzumab govitecan Sacituzumab govitecan myths Low counts, fever risk and hair loss on sacituzumab govitecan Sacituzumab govitecan infusion days Sacituzumab govitecan side effects Sacituzumab govitecan for triple-negative breast cancer Sacituzumab govitecan vs standard chemotherapy in triple negative breast cancer How newer drugs are sequenced with older ones

Metastatic Breast Cancer

What comes after a CDK4/6 inhibitor stops working? Ascites and abdominal swelling in advanced breast cancer Is my back pain bone metastasis or something else? Bone marrow involvement in advanced breast cancer Bone metastases in breast cancer Brain metastases in breast cancer Tumour markers CA 15-3 and CEA in metastatic breast cancer Chest wall and local recurrence after mastectomy Clinical trials in metastatic breast cancer Cost of long-term metastatic breast cancer treatment in India Explaining metastatic breast cancer to family and friends First-line treatment for hormone-positive metastatic breast cancer Confusion, thirst and drowsiness Lines of treatment in metastatic breast cancer Liver metastases in breast cancer Living well with metastatic breast cancer for years Lung metastases and pleural effusion in breast cancer Malignant pleural effusion Metastatic breast cancer and pink-ribbon culture Prognosis in metastatic breast cancer Treatment sequence in metastatic HER2-positive breast cancer Treatment options in metastatic triple negative breast cancer Oligometastatic breast cancer Why receptors are re-tested on a metastatic biopsy Scan intervals and monitoring in metastatic disease Understanding scan reports in metastatic breast cancer Skin metastases and nodules on the chest Surgery and radiation in metastatic breast cancer Treatment holidays and breaks in metastatic breast cancer When do doctors switch treatment in metastatic disease? Where breast cancer spreads and what each site feels like Working and earning with metastatic breast cancer
Call now Book free consultation